Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which blood pressure combo works best after a heart stent?

NCT ID NCT07683585

Disease control Sponsor: National Medical Research Center for Therapy and Preventive Medicine Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This trial compares two different dual blood pressure medications in people aged 50–70 with high blood pressure and heart disease who have just received a heart stent. Participants are randomly assigned to one of two drug combinations: losartan plus hydrochlorothiazide or amlodipine plus azilsartan. The study measures how well each combination lowers blood pressure, affects chest pain, and impacts daily life over 12 weeks after leaving the hospital.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Losartan + Hydrochlorothiazide and Amlodipine + Azilsartan
What this could lead to
If one combination works better, it could improve blood pressure control and quality of life for people who have had a heart stent.
What could go wrong
This is a small, early-stage study, so results may not apply to everyone. Both treatments are already approved, so no major new breakthrough is expected.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 207 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 50 to 70 years * Arterial hypertension * Coronary artery disease * Hospitalization for elective percutaneous coronary intervention * Coronary artery stenting during the current hospitalization * Requirement for dual antihypertensive therapy * Treatment with beta-blockers, lipid-lowering therapy, and antiplatelet therapy * Ability and willingness to provide written informed consent Exclusion Criteria: * Refusal or inability to provide informed consent * Acute coronary syndrome * Active malignancy * Pulmonary embolism * Chronic kidney disease stage 4-5 * Type 2 diabetes mellitus * Contraindications or intolerance to study medications, including bilateral renal artery stenosis, hyperkalemia, hyperuricemia, or gout * Women of reproductive age * Permanent or persistent atrial fibrillation * Planned staged coronary stenting * Heart failure with reduced ejection fraction * Any other condition that, in the investigator's opinion, may interfere with participation in the study or interpretation of study results

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Coronary arterial disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

coronary artery disorder hypertensive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Coronary arterial disease Hypertension Percutaneous coronary intervention

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • National Medical Research Center for Therapy and Preventive Medicine

    RECRUITING

    Moscow, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.